Literature DB >> 19369565

Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice.

Rachel A Karlnoski1, Arnon Rosenthal, Dione Kobayashi, Jaume Pons, Jennifer Alamed, Mary Mercer, Qingyou Li, Marcia N Gordon, Paul E Gottschall, David Morgan.   

Abstract

In amyloid precursor protein (APP) models of amyloid deposition, the amount of amyloid deposits increase with mouse age. At a first approximation, the extent of amyloid accumulation may either reflect small excesses of production over clearance that accumulate over time or, alternatively, indicate a steady-state equilibrium at that age, reflecting the instantaneous excess of production over clearance, which increases as the organism ages. To discriminate between these options, we reversibly suppressed amyloid deposition in Tg2576 mice with the anti-Abeta antibody 2H6, starting at 8 months, just before the first histological deposits can be discerned. Six months later, we stopped the suppression and monitored the progression of amyloid accumulation in control APP mice and suppressed APP mice over the next 3 months. The accumulation hypothesis would predict that the rate of amyloid from 14 to 17 months would be similar in the suppressed and control mice, while the equilibrium hypothesis would predict that the increase would be faster in the suppressed group, possibly catching up completely with the control mice. The results strongly support the accumulation hypothesis, with no evidence of the suppressed mice catching up with the control mice as predicted by equilibrium models. If anything, there was a slower rate of increase in the suppressed APP mice than the control mice, suggesting that a slow seeding mechanism likely precedes a rapid fibrillogenesis in determining the extent of amyloid deposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369565      PMCID: PMC2688812          DOI: 10.1523/JNEUROSCI.4560-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  30 in total

1.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43).

Authors:  D M Mann; T Iwatsubo; N J Cairns; P L Lantos; D Nochlin; S M Sumi; T D Bird; P Poorkaj; J Hardy; M Hutton; G Prihar; R Crook; M N Rossor; M Haltia
Journal:  Ann Neurol       Date:  1996-08       Impact factor: 10.422

3.  Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.

Authors:  Yona Levites; Karen Jansen; Lisa A Smithson; Rachel Dakin; Vallie M Holloway; Pritam Das; Todd E Golde
Journal:  J Neurosci       Date:  2006-11-15       Impact factor: 6.167

4.  Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.

Authors:  Antonella Caccamo; Salvatore Oddo; Michael C Sugarman; Yama Akbari; Frank M LaFerla
Journal:  Neurobiol Aging       Date:  2005-05       Impact factor: 4.673

5.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Authors:  L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

6.  The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.

Authors:  Jonathan D Best; David W Smith; Michael A Reilly; Ruth O'Donnell; Huw D Lewis; Semantha Ellis; Neil Wilkie; Thomas W Rosahl; Philippe A Laroque; Christine Boussiquet-Leroux; Ian Churcher; John R Atack; Timothy Harrison; Mark S Shearman
Journal:  J Pharmacol Exp Ther       Date:  2006-11-10       Impact factor: 4.030

7.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

8.  Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice.

Authors:  Neelima B Chauhan; George J Siegel; Terry Lichtor
Journal:  J Neurosci Res       Date:  2004-12-01       Impact factor: 4.164

9.  Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease.

Authors:  Joanna L Jankowsky; Hilda H Slunt; Victoria Gonzales; Alena V Savonenko; Jason C Wen; Nancy A Jenkins; Neal G Copeland; Linda H Younkin; Henry A Lester; Steven G Younkin; David R Borchelt
Journal:  PLoS Med       Date:  2005-11-15       Impact factor: 11.069

10.  Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies.

Authors:  Qingyou Li; Marcia Gordon; Chuanhai Cao; Kenneth E Ugen; Dave Morgan
Journal:  BMC Neurosci       Date:  2007-03-20       Impact factor: 3.288

View more
  16 in total

1.  Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.

Authors:  Allan Wang; Pritam Das; Robert C Switzer; Todd E Golde; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

2.  The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase NEDD4-1.

Authors:  Begum G Akkaya; Joseph K Zolnerciks; Tasha K Ritchie; Bjoern Bauer; Anika M S Hartz; James A Sullivan; Kenneth J Linton
Journal:  Mol Membr Biol       Date:  2015-05-26       Impact factor: 2.857

3.  Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load.

Authors:  Qingyou Li; Lori Lebson; Daniel C Lee; Kevin Nash; Jan Grimm; Arnon Rosenthal; Maj-Linda B Selenica; Dave Morgan; Marcia N Gordon
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-27       Impact factor: 4.147

Review 4.  Immunotherapy for Alzheimer's disease.

Authors:  D Morgan
Journal:  J Intern Med       Date:  2011-01       Impact factor: 8.989

5.  Evidence against a role of P-glycoprotein in the clearance of the Alzheimer's disease Aβ1-42 peptides.

Authors:  Ivan Bello; Milena Salerno
Journal:  Cell Stress Chaperones       Date:  2015-01-16       Impact factor: 3.667

Review 6.  The case for low-level BACE1 inhibition for the prevention of Alzheimer disease.

Authors:  Eric McDade; Iryna Voytyuk; Paul Aisen; Randall J Bateman; Maria C Carrillo; Bart De Strooper; Christian Haass; Eric M Reiman; Reisa Sperling; Pierre N Tariot; Riqiang Yan; Colin L Masters; Robert Vassar; Stefan F Lichtenthaler
Journal:  Nat Rev Neurol       Date:  2021-09-21       Impact factor: 42.937

Review 7.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

Review 8.  Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer's Disease with Positron Emission Tomography.

Authors:  Fang Xie; Fangyu Peng
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.

Authors:  Anika M S Hartz; David S Miller; Björn Bauer
Journal:  Mol Pharmacol       Date:  2010-01-25       Impact factor: 4.436

10.  Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology.

Authors:  Pritam Das; Christophe Verbeeck; Lisa Minter; Paramita Chakrabarty; Kevin Felsenstein; Thomas Kukar; Ghulam Maharvi; Abdul Fauq; Barbara A Osborne; Todd E Golde
Journal:  Mol Neurodegener       Date:  2012-08-14       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.